Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermo Stable Flolan Lifestyle Impact in PAH
NCT01462565Phase 4Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- May 2012
- Countries
- 3
01
Overview
Phase 4, open-label trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoints: Medical Outcomes Study Short Form 36 at Week 4 and Study Specific Participant Acceptance Survey at Week 4. Started Nov 2011; status: completed.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01462565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462565.